Imagine your body has a built-in security team that can kill germs, but sometimes they are asleep. Instead of bringing in outside chemicals like antibiotics that germs can learn to beat, this technology uses a wake-up call to tell your own body to produce its own natural germ-fighters. It's like teaching your immune system to fight the battle itself rather than relying on external medicine.
The clinical pipeline for new antibiotics is dry, while antimicrobial resistance causes 33,000 deaths annually in Europe. Traditional antibiotics create selection pressure that leads to further resistance.
A screening and optimization process to identify lead molecules that trigger the human body to produce its own antimicrobial peptides.
If you are a drug discovery firm dealing with a dry clinical pipeline for new antimicrobials — this project developed a method to identify and optimize lead molecules that boost human antimicrobial peptides. This provides a sustainable way to treat infections without increasing the risk of resistance.
If you are a biotech startup dealing with the search for new active compounds — this project explored the marine microbiome to find molecules with AMP-inducer properties. This opens a new source for developing drug candidates for inflammatory pathologies.
If you are an animal health company dealing with the spread of resistance in the environment — this project developed a technology that reduces selection pressure on bacteria. This helps protect animals and the environment from the spread of AMR.
Based on available project data, there is no information regarding the specific cost or pricing of the resulting drug candidates.
The project focuses on establishing proof-of-concept and identifying lead molecules for the R&D pipeline. Industrial scaling details are not provided in the current project data.
Based on available project data, the project aims to turn active molecules into drug candidates, but specific licensing or patent terms are not listed.
The project runs from 2024-01-01 to 2027-12-31, with the objective of pushing lead molecules toward a phase I clinical trial.
The technology is designed to promote an endogenous response, which may be used in situations of endemic infections or inflammatory pathologies in industrialized countries.
The consortium consists of 7 partners across 3 countries (DE, FR, SE). It is heavily weighted toward research and academia, with 4 research organizations and 2 universities, while only 1 SME (14% industry ratio) is involved, indicating the project is currently in a high-science, early-stage development phase.
Contact Ecole Normale Superieure in France
Contact us to explore licensing opportunities for AMP-inducer lead molecules.
